By Ben Butkus

LONDON – Representatives from big pharma weighed in on the increasing use of quantitative PCR in areas such as companion diagnostic development and vaccine analytical testing, and provided common pitfalls and tips for success in applying the technique at a qPCR industry meeting held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.